Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2022-05-25 AGM Information
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Oxurion NV_BAV_20220524.pdf
AGM Information Classification · 99% confidence The document is a notarial record ('proces-verbaal') detailing the proceedings and resolutions of an 'BUITENGEWONE ALGEMENE VERGADERING' (Extraordinary General Meeting or EGM) of the company 'Oxurion'. The agenda items explicitly concern corporate actions: 'GOEDKEURING VAN EEN AANDELENHERGROEPERING' (Approval of a share consolidation/reverse split) and granting new authorizations to the Board regarding authorized capital and share buybacks. Since this document records the formal decisions made at a shareholder meeting, it aligns best with the category for AGM/EGM related materials, which is AGM-R (AGM Information), even though it is an EGM, as AGM-R covers general meeting materials. It is a formal record of decisions, not just a presentation or a simple announcement of a vote result (DVA).
2022-05-25 Dutch
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)
Earnings Release Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and contains "Regulated Information – Inside Information." It announces the top-line results of a clinical trial (INTEGRAL trial for THR-687) and details the company's decision to discontinue that program and focus on another (THR-149). This structure—announcing key financial/operational results for a period or event outside of a formal quarterly/annual filing—is characteristic of an Earnings Release (ER). While it contains operational updates, its primary function is the immediate release of material performance information (clinical trial outcomes impacting future revenue/strategy). It is not a full Annual Report (10-K), an Interim Report (IR), or a transcript (CT). It is the initial, high-level announcement of results. Q2 2022
2022-05-09 English
Oxurion Kondigt Top-Line Resultaten aan van Deel A van Fase 2 van de INTEGRAL-Studie waarin het Effect van THR-687 Wordt Onderzocht voor de Behandeling van Diabetisch Macula-Oedeem (DME)
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as "*PERSBERICHT*" (Press Release) and contains "Gereglementeerde informatie – Voorkennis" (Regulated information – Inside information). It announces the top-line results of a clinical trial (INTEGRAL study for THR-687) and provides management commentary, concluding with contact information. This structure is characteristic of an initial announcement of financial or operational results, rather than the full, detailed report itself (like a 10-K or IR). Since it announces key financial/operational outcomes (clinical trial results) immediately, it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results or significant operational milestones. Although it's a clinical trial result, in the context of biotech/pharma, these announcements often serve the same function as an earnings release regarding period performance highlights. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Given the focus on announcing key results immediately, ER is the most appropriate fit among the provided options.
2022-05-09 Dutch
Oxurion NV_Special Report BoD_authorized share capital_20220331 (NL).pdf
Capital/Financing Update Classification · 98% confidence The document is titled "BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG ARTIKEL 7:199 VAN HET WETBOEK VAN VENNOOTSCHAPPEN EN VERENIGINGEN" (Special Report of the Board of Directors pursuant to Article 7:199 of the Companies and Associations Code). It explicitly discusses proposals to grant the Board of Directors authorization to increase the company's capital within the framework of authorized capital, including provisions for issuing shares, convertible bonds, and waiving pre-emptive rights. This type of document, detailing management's proposal regarding capital structure changes and seeking shareholder approval (to be presented at the BAV - Extraordinary General Meeting), strongly aligns with documents related to capital structure changes and financing activities. The core subject is the authorization for capital increase, which falls under 'Capital/Financing Update' (CAP). While it is a report presented to a meeting, its content is specifically about capital authorization, making CAP more precise than a general AGM-R or RPA.
2022-05-06 Dutch
Oxurion NV_Proxy form EGM_24 May 2022 (NL-ENG).pdf
AGM Information Classification · 99% confidence The document is titled "VOLMACHT VOOR DE BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS VAN 24 MEI 2022" (Proxy for the Extraordinary General Meeting of Shareholders of May 24, 2022). It explicitly details the process for shareholders to grant a proxy (volmacht) to a representative to vote on the agenda items for an upcoming Extraordinary General Meeting (EGM). The agenda items concern a share consolidation (1-for-10 reverse split) and authorization for the board regarding authorized capital. This document is a proxy form/information related to soliciting shareholder votes for a general meeting, which aligns directly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the minutes of the meeting (AGM-R) or the results of the vote (DVA), but the material used to facilitate voting.
2022-05-06 Dutch
Oxurion NV_Shareholders' Rights EGM_24 May 2022 (NL-ENG).pdf
AGM Information Classification · 98% confidence The document explicitly discusses procedures and rights related to an upcoming 'extraordinary general shareholders' meeting' scheduled for 'Tuesday 24 May 2022'. It details the right of shareholders to submit written questions prior to this meeting and sets deadlines for registration and question submission. This content is directly related to the preparation and conduct of a shareholder meeting, specifically concerning the information provided to attendees or potential attendees regarding voting rights, agenda items, and procedures for asking questions. This aligns most closely with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings, or potentially AGM-R if it were the meeting materials themselves. Since this focuses on the procedural rights leading up to the meeting (asking questions), PSI is the most appropriate fit, as it covers pre-meeting information dissemination.
2022-05-06 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.